Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

Anna S. Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G. Ghany, Jean Michel Pawlotsky, Yun Fan Liaw, Masashi Mizokami, Carla Kuiken, Rajen Koshy, T. Jake Liang, William Mason

Research output: Contribution to journalArticle

Abstract

Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

Original languageEnglish (US)
Pages (from-to)254-265
Number of pages12
JournalHepatology
Volume46
Issue number1
DOIs
StatePublished - Jul 2007
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management'. Together they form a unique fingerprint.

  • Cite this

    Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J. M., Liaw, Y. F., Mizokami, M., Kuiken, C., Koshy, R., Liang, T. J., & Mason, W. (2007). Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology, 46(1), 254-265. https://doi.org/10.1002/hep.21698